Aclaris Therapeutics

Nu Skin Enterprises, Inc.

Forte Biosciences

Dermata Therapeutics, Inc.

Connect Biopharma

Short interest: 6.49% of float, squeeze risk: MODERATE

Dilution score: 18/100 (LOW), 24.0 months cash

179 PubMed publications found for Aclaris

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.

Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors.

Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability.

Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis.

Dilution score: 10/100 (LOW), 39.3 months cash

Short interest: 6.97% of float, squeeze risk: MODERATE

Short interest: 7.47% of float, squeeze risk: MODERATE

Dilution score: 12/100 (LOW), 39.3 months cash

Short interest: 8.16% of float, squeeze risk: MODERATE

SW convergence: 55/100 (Neutral), 1 bullish / 0 bearish signals

SW convergence: 50/100 (Neutral), 0 bullish / 0 bearish signals

Short interest: 8.47% of float, squeeze risk: MODERATE

SW convergence: 50/100 (Neutral), 1 bullish / 1 bearish signals

Dilution score: 18/100 (LOW), 35.6 months cash

178 PubMed publications found for Aclaris

Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP).

Short interest: 8.52% of float, squeeze risk: MODERATE

<article class="bts-verified-summary" data-ticker="ACRS">
<p>Aclaris Therapeutics (ACRS) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-2">[2]</a></sup>, including 1 Phase 2<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>No Form 4 insider filings for ACRS were recorded at the SEC in the past 30 days<sup><a href="#fn-3">[3]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Aclaris+Therapeutics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Aclaris+Therapeutics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">SEC EDGAR · 0001557746 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22ACRS%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001557746

Aclaris Therapeutics (ACRS) — BioTechSigns Verified Summary

Aclaris Therapeutics (ACRS) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 2[1].

No Form 4 insider filings for ACRS were recorded at the SEC in the past 30 days[3].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Aclaris+Therapeutics%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Aclaris+Therapeutics%22&aggFilters=status%3Arec%2Cact
[3] SEC EDGAR, 0001557746. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22ACRS%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.